Skip to content

Author

K. Giblin

We have 2 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

BACKGROUND Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with ob...

Virginia Bellido, C. L. le Roux, E. Ekinci et al. · 1 citation
Jul 2026

Generative AI-Assisted Discovery of HPK1 Inhibitors.

An early application of REINVENT, AstraZeneca's in-house generative molecular design platform, is described to identify new inhibitor scaffolds for hematopoietic progenitor kinase 1 (HPK1), demonstrating the value of integrating generative AI with medicinal chemistry expertise.

K. Giblin, Kun Song, Hongming Chen et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.